Robert M. Minutello
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Robert M. Minutello has a total of 82 co-authors. Here are the top co-authors by number of shared publications:
- Shing Chiu Wong
Division of Cardiology, Department of Medicine, Weill Cornell Medicine, New York, NY 10021, USA
10 shared publications - Geoffrey Bergman
Department of Medicine, Division of Cardiology, Weill Cornell Medicine – New York Presbyterian Hospital, Weill Cornell Cardiovascular Outcomes Research Group (CORG) and the Greenberg Institute for Cardiac Electrophysiology, NY (E.V.R., C.F.L., S.C.W., G.B., J.E.I., G.T., S.M.M., B.B.L., L.K.K., J.W.C.).
8 shared publications Dmitriy N. Feldman
Division of Cardiology, Department of Medicine, Weill Cornell Medicine New York‐Presbyterian Hospital New York NY
7 shared publications- Luke K. Kim
Weill Cornell Cardiovascular Outcomes Research Group (CORG), Weill Cornell Medical College, New York, NY 10021, USA
7 shared publications - Harsimran Sachdeva Singh
Weill Cornell Medicine, New York Presbyterian Hospital, New York, New York, USA
5 shared publications - Ilhwan Yeo
Department of Medicine, Division of Cardiology, Weill Cornell Medicine—New York Presbyterian Hospital and Weill Cornell Cardiovascular Outcomes Research Group (CORG) , 520 East 70th Street 4th Floor, New York, NY 10021
4 shared publications
Latest Publications
- 1 March 2024
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 17 (3) , e011115
Impact of Advanced Therapy Centers on Characteristics and Outcomes of Heart Failure Admissions
BACKGROUND: Although much attention has been paid to admission and transfer patterns for cardiogenic shock, contemporary data are lacking on decompensated heart failure (HF) admissions and transfers and the impact of advanced therapy centers (ATCs) on outcomes. METHODS: HF hospitalizations were obtained from the Nationwide Readmissions Database 2016 to 2019. Centers performing at least 1 heart transplant or left ventricular assist device were classified as ATCs. Patient characteristics, outcomes, and procedural volume were compared among 3 cohorts: admissions to non-ATCs, admissions to ATCs, and transfers to ATCs. A secondary analysis evaluated outcomes for severe HF hospitalizations (cardiogenic shock, cardiac arrest, and mechanical ventilation). Multivariable logistic regression was performed to adjust for the presence of HF decompensations and significant clinical variables during univariate analysis. RESULTS: A total of 2 331 690 hospitalizations (81.2%) were admissions to non-ATCs (94.5% of centers), 525 037 (18.3%) were admissions to ATCs (5.5% of centers), and 15 541 (0.5%) were transferred to ATCs. Patients treated at ATCs (especially those transferred) had higher rates of HF decompensations, procedural frequency, lengths of stay, and costs. Unadjusted mortality was 2.6% at non-ATCs and was higher at ATCs, both for directly admitted (2.9%, P P P P P P <0.001) patients, with similarly lower multivariable-adjusted mortality. CONCLUSIONS: Patients with HF treated at ATCs were sicker but associated with higher procedural volume and lower adjusted mortality.
- 1 March 2024
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 17 (3) , e011115
Impact of Advanced Therapy Centers on Characteristics and Outcomes of Heart Failure Admissions
BACKGROUND: Although much attention has been paid to admission and transfer patterns for cardiogenic shock, contemporary data are lacking on decompensated heart failure (HF) admissions and transfers and the impact of advanced therapy centers (ATCs) on outcomes. METHODS: HF hospitalizations were obtained from the Nationwide Readmissions Database 2016 to 2019. Centers performing at least 1 heart transplant or left ventricular assist device were classified as ATCs. Patient characteristics, outcomes, and procedural volume were compared among 3 cohorts: admissions to non-ATCs, admissions to ATCs, and transfers to ATCs. A secondary analysis evaluated outcomes for severe HF hospitalizations (cardiogenic shock, cardiac arrest, and mechanical ventilation). Multivariable logistic regression was performed to adjust for the presence of HF decompensations and significant clinical variables during univariate analysis. RESULTS: A total of 2 331 690 hospitalizations (81.2%) were admissions to non-ATCs (94.5% of centers), 525 037 (18.3%) were admissions to ATCs (5.5% of centers), and 15 541 (0.5%) were transferred to ATCs. Patients treated at ATCs (especially those transferred) had higher rates of HF decompensations, procedural frequency, lengths of stay, and costs. Unadjusted mortality was 2.6% at non-ATCs and was higher at ATCs, both for directly admitted (2.9%, P P P P P P <0.001) patients, with similarly lower multivariable-adjusted mortality. CONCLUSIONS: Patients with HF treated at ATCs were sicker but associated with higher procedural volume and lower adjusted mortality.
- Open Access
- 6 February 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (3) , e032607
Impella Versus Intra‐Aortic Balloon Pump in Patients With Cardiogenic Shock Treated With Venoarterial Extracorporeal Membrane Oxygenation: An Observational Study
Background: Venoarterial extracorporeal membrane oxygenation (VA‐ECMO) is increasingly used for patients with cardiogenic shock. Although Impella or intra‐aortic balloon pump (IABP) is frequently used for left ventricular unloading (LVU) during VA‐ECMO treatment, there are limited data on comparative outcomes. We compared outcomes of Impella and IABP for LVU during VA‐ECMO. Methods and Results: Using the Nationwide Readmissions Database between 2016 and 2020, we analyzed outcomes in 3 groups of patients with cardiogenic shock requiring VA‐ECMO based on LVU strategies: extracorporeal membrane oxygenation (ECMO) only, ECMO with IABP, and ECMO with Impella. Of 15 980 patients on VA‐ECMO, IABP and Impella were used in 19.4% and 16.4%, respectively. The proportion of patients receiving Impella significantly increased from 2016 to 2020 (6.5% versus 25.8%; P ‐trendP =0.02). ECMO with Impella versus ECMO only had similar in‐hospital mortality (aOR, 1.09; P =0.695) but was associated with more bleeding (aOR, 1.21; P =0.007) and more acute kidney injury requiring hemodialysis (aOR, 1.42; P P =0.002), higher in‐hospital mortality (aOR, 1.32; P =0.001), and higher 40‐day mortality (hazard ratio, 1.25; P <0.001). Conclusions: In patients with cardiogenic shock on VA‐ECMO, LVU with Impella, particularly with 2.5/CP, was not associated with improved survival at 40 days but was associated with increased adverse events compared with IABP. More data are needed to assess Impella platform‐specific comparative outcomes of LVU.
- 6 February 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (3) , e032607
Open AccessImpella Versus Intra‐Aortic Balloon Pump in Patients With Cardiogenic Shock Treated With Venoarterial Extracorporeal Membrane Oxygenation: An Observational Study
Background: Venoarterial extracorporeal membrane oxygenation (VA‐ECMO) is increasingly used for patients with cardiogenic shock. Although Impella or intra‐aortic balloon pump (IABP) is frequently used for left ventricular unloading (LVU) during VA‐ECMO treatment, there are limited data on comparative outcomes. We compared outcomes of Impella and IABP for LVU during VA‐ECMO. Methods and Results: Using the Nationwide Readmissions Database between 2016 and 2020, we analyzed outcomes in 3 groups of patients with cardiogenic shock requiring VA‐ECMO based on LVU strategies: extracorporeal membrane oxygenation (ECMO) only, ECMO with IABP, and ECMO with Impella. Of 15 980 patients on VA‐ECMO, IABP and Impella were used in 19.4% and 16.4%, respectively. The proportion of patients receiving Impella significantly increased from 2016 to 2020 (6.5% versus 25.8%; P ‐trendP =0.02). ECMO with Impella versus ECMO only had similar in‐hospital mortality (aOR, 1.09; P =0.695) but was associated with more bleeding (aOR, 1.21; P =0.007) and more acute kidney injury requiring hemodialysis (aOR, 1.42; P P =0.002), higher in‐hospital mortality (aOR, 1.32; P =0.001), and higher 40‐day mortality (hazard ratio, 1.25; P <0.001). Conclusions: In patients with cardiogenic shock on VA‐ECMO, LVU with Impella, particularly with 2.5/CP, was not associated with improved survival at 40 days but was associated with increased adverse events compared with IABP. More data are needed to assess Impella platform‐specific comparative outcomes of LVU.
- Open Access
Impact of Advanced Therapy Centers on Characteristics and Outcomes of Heart Failure Admissions
Background Although much attention has been paid to admission and transfer patterns for cardiogenic shock, contemporary data is lacking on decompensated heart failure (HF) admissions and transfers, and the impact of advanced therapy centers (ATCs) on outcomes. Methods HF hospitalizations were obtained from the Nationwide Readmissions Database 2016-2019. Centers performing at least one heart transplant or left ventricular assist device were classified as ATCs. Patient characteristics, outcomes, and procedural volume were compared among three cohorts: admissions to non-ATCs, admissions to ATCs, transfers to ATCs. A secondary analysis evaluated outcomes for severe HF hospitalizations (cardiogenic shock, cardiac arrest, mechanical ventilation). Results 2,331,690 hospitalizations were admissions to non-ATCs (94.5% of centers), 525,037 were admissions to ATCs (5.5% of centers), and 15,541 were transfers to ATCs. Patients treated at ATCs (especially those transferred) had higher rates of HF decompensations, procedural frequency, lengths-of-stay, and costs. Unadjusted mortality was 2.6% at non-ATCs and was higher at ATCs, both for directly admitted (2.9%, pConclusions HF patients treated at ATCs were sicker but associated with higher procedural volume and lower adjusted mortality. Clinical Perspective Contemporary data is lacking on admissions and transfers for decompensated heart failure (HF) and the impact of advanced therapy centers (ATCs) on outcomes. Our findings show that decompensated HF patients treated at ATCs had higher rates of HF decompensations, procedural frequency, lengths-of-stay, and costs. While unadjusted mortality was higher at ATCs, multivariable adjusted mortality was significantly lower at ATCs, both for directly admitted and transferred patients. Our findings will hopefully prompt earlier recognition and referral of patients to ATCs, emphasize the need for increased numbers of ATCs, and spark further research into the decision-making process for referral to ATCs.
Open AccessImpact of Advanced Therapy Centers on Characteristics and Outcomes of Heart Failure Admissions
Background Although much attention has been paid to admission and transfer patterns for cardiogenic shock, contemporary data is lacking on decompensated heart failure (HF) admissions and transfers, and the impact of advanced therapy centers (ATCs) on outcomes. Methods HF hospitalizations were obtained from the Nationwide Readmissions Database 2016-2019. Centers performing at least one heart transplant or left ventricular assist device were classified as ATCs. Patient characteristics, outcomes, and procedural volume were compared among three cohorts: admissions to non-ATCs, admissions to ATCs, transfers to ATCs. A secondary analysis evaluated outcomes for severe HF hospitalizations (cardiogenic shock, cardiac arrest, mechanical ventilation). Results 2,331,690 hospitalizations were admissions to non-ATCs (94.5% of centers), 525,037 were admissions to ATCs (5.5% of centers), and 15,541 were transfers to ATCs. Patients treated at ATCs (especially those transferred) had higher rates of HF decompensations, procedural frequency, lengths-of-stay, and costs. Unadjusted mortality was 2.6% at non-ATCs and was higher at ATCs, both for directly admitted (2.9%, pConclusions HF patients treated at ATCs were sicker but associated with higher procedural volume and lower adjusted mortality. Clinical Perspective Contemporary data is lacking on admissions and transfers for decompensated heart failure (HF) and the impact of advanced therapy centers (ATCs) on outcomes. Our findings show that decompensated HF patients treated at ATCs had higher rates of HF decompensations, procedural frequency, lengths-of-stay, and costs. While unadjusted mortality was higher at ATCs, multivariable adjusted mortality was significantly lower at ATCs, both for directly admitted and transferred patients. Our findings will hopefully prompt earlier recognition and referral of patients to ATCs, emphasize the need for increased numbers of ATCs, and spark further research into the decision-making process for referral to ATCs.
- Open Access
- 29 June 2023
- Published by Elsevier in Journal of the Society for Cardiovascular Angiography & Interventions
- Vol. 2 (5)
Feasibility and Safety of Impella-Assisted High-Risk PCI Before TAVR in Patients With Severe Aortic Stenosis
- 29 June 2023
- Published by Elsevier in Journal of the Society for Cardiovascular Angiography & Interventions
- Vol. 2 (5)
Open AccessFeasibility and Safety of Impella-Assisted High-Risk PCI Before TAVR in Patients With Severe Aortic Stenosis
- Open Access
- 20 August 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (16) , 3701
Thirty-Day Readmission Rates after Takotsubo Syndrome with or without Malignancy: A Nationwide Readmissions Database Analysis
The association between malignancy and readmission after Takotsubo syndrome (TTS) hospitalization has not been fully described. We sought to examine the rates, cause, and cost of 30-day readmissions of TTS, with or without malignancy, by utilizing Nationwide Readmissions Databases from 2010 to 2014. We identified 61,588 index hospitalizations for TTS. TTS patients with malignancy tended to be older (70.6 ± 0.2 vs. 66.1 ± 0.1, p < 0.001), and the overall burden of comorbidities was higher than in those without malignancy. TTS patients with malignancy had significantly higher 30-day readmission rates than those without malignancy (15.9% vs. 11.0%; odds ratio (OR), 1.35; 95% confidence interval (CI), 1.18–1.56). Non-cardiac causes were the most common causes of readmission for TTS patients with malignancy versus without malignancy (75.5% vs. 68.1%, p < 0.001). The 30-day readmission rate due to recurrent TTS was very low in both groups (0.4% and 0.5%; p = 0.47). The total costs were higher by 25% (p < 0.001) in TTS patients with vs. without malignancy. In summary, among patients hospitalized with TTS, the presence of malignancy was associated with increased risk of 30-day readmission and increased costs. These findings highlight the importance of optimized management for TTS patients with malignancy.
- 20 August 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (16) , 3701
Open AccessThirty-Day Readmission Rates after Takotsubo Syndrome with or without Malignancy: A Nationwide Readmissions Database Analysis
The association between malignancy and readmission after Takotsubo syndrome (TTS) hospitalization has not been fully described. We sought to examine the rates, cause, and cost of 30-day readmissions of TTS, with or without malignancy, by utilizing Nationwide Readmissions Databases from 2010 to 2014. We identified 61,588 index hospitalizations for TTS. TTS patients with malignancy tended to be older (70.6 ± 0.2 vs. 66.1 ± 0.1, p < 0.001), and the overall burden of comorbidities was higher than in those without malignancy. TTS patients with malignancy had significantly higher 30-day readmission rates than those without malignancy (15.9% vs. 11.0%; odds ratio (OR), 1.35; 95% confidence interval (CI), 1.18–1.56). Non-cardiac causes were the most common causes of readmission for TTS patients with malignancy versus without malignancy (75.5% vs. 68.1%, p < 0.001). The 30-day readmission rate due to recurrent TTS was very low in both groups (0.4% and 0.5%; p = 0.47). The total costs were higher by 25% (p < 0.001) in TTS patients with vs. without malignancy. In summary, among patients hospitalized with TTS, the presence of malignancy was associated with increased risk of 30-day readmission and increased costs. These findings highlight the importance of optimized management for TTS patients with malignancy.
- 1 November 2019
- Published by Wolters Kluwer Health in Cardiology in Review
- Vol. 27 (6) , 327-336
Functional Mitral Regurgitation in Heart Failure
Functional mitral regurgitation (FMR) in the setting of left ventricular (LV) dysfunction and heart failure portends a poor prognosis. Guideline-directed medical therapy remains the cornerstone of initial treatment, with emphasis placed on treatment of the underlying LV dysfunction, as FMR is a secondary phenomenon and a disease due to LV remodeling. Surgical correction of FMR is controversial because it typically does not address the underlying mechanism and etiology of the condition. However, new, minimally invasive transcatheter therapies, in particular the MitraClip system, have shown promise in the treatment of FMR in selected patients. This review will summarize the pathophysiology underlying FMR, the prognosis of patients with heart failure and FMR, and the various medical and procedural treatment options currently available and under investigation.
- 1 November 2019
- Published by Wolters Kluwer Health in Cardiology in Review
- Vol. 27 (6) , 327-336
Functional Mitral Regurgitation in Heart Failure
Functional mitral regurgitation (FMR) in the setting of left ventricular (LV) dysfunction and heart failure portends a poor prognosis. Guideline-directed medical therapy remains the cornerstone of initial treatment, with emphasis placed on treatment of the underlying LV dysfunction, as FMR is a secondary phenomenon and a disease due to LV remodeling. Surgical correction of FMR is controversial because it typically does not address the underlying mechanism and etiology of the condition. However, new, minimally invasive transcatheter therapies, in particular the MitraClip system, have shown promise in the treatment of FMR in selected patients. This review will summarize the pathophysiology underlying FMR, the prognosis of patients with heart failure and FMR, and the various medical and procedural treatment options currently available and under investigation.
- 1 June 2019
- Published by Elsevier in Cardiovascular Revascularization Medicine
- Vol. 20 (6) , 468-474
The Influence of Gender on In-Hospital Clinical Outcome Following Isolated Mitral or Aortic Heart Valve Surgery
- 1 June 2019
- Published by Elsevier in Cardiovascular Revascularization Medicine
- Vol. 20 (6) , 468-474
The Influence of Gender on In-Hospital Clinical Outcome Following Isolated Mitral or Aortic Heart Valve Surgery
- 1 January 2018
- Published by Elsevier in The American Journal of Medicine
- Vol. 131 (1) , 100.e9-100.e20
Temporal Trends in the Clinical Acuity of Patients with ST-Segment Elevation Myocardial Infarction
- 1 January 2018
- Published by Elsevier in The American Journal of Medicine
- Vol. 131 (1) , 100.e9-100.e20
Temporal Trends in the Clinical Acuity of Patients with ST-Segment Elevation Myocardial Infarction
- 1 April 2017
- Published by Elsevier in International Journal of Cardiology
- Vol. 232, 140-146
Analysis of reperfusion time trends in patients with ST-elevation myocardial infarction across New York State from 2004 to 2012
- 1 April 2017
- Published by Elsevier in International Journal of Cardiology
- Vol. 232, 140-146
Analysis of reperfusion time trends in patients with ST-elevation myocardial infarction across New York State from 2004 to 2012